Celgene (NASDAQ:CELG) was downgraded by Vetr from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday. They presently have a $121.72 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective points to a potential upside of 11.63% from the company’s current price.

Several other brokerages have also recently weighed in on CELG. BMO Capital Markets increased their price objective on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, November 17th. Oppenheimer reiterated a “buy” rating and issued a $170.00 price objective on shares of Celgene in a research note on Friday, October 20th. Cann reiterated a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research note on Friday, October 27th. Finally, Citigroup lowered their price objective on shares of Celgene from $140.00 to $102.00 and set a “neutral” rating on the stock in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and an average target price of $138.81.

Shares of Celgene (CELG) traded up $1.04 during trading hours on Tuesday, hitting $109.04. 5,122,695 shares of the stock traded hands, compared to its average volume of 4,782,211. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market cap of $83,526.45, a PE ratio of 16.58, a PEG ratio of 0.82 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the business earned $1.58 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene will post 6.67 earnings per share for the current year.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.95% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in CELG. Janus Henderson Group PLC grew its holdings in Celgene by 4,290.5% during the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after buying an additional 8,217,433 shares in the last quarter. BlackRock Inc. grew its holdings in Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new position in shares of Celgene in the second quarter valued at $271,605,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after purchasing an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. 80.16% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/13/celgene-celg-downgraded-by-vetr-to-buy.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.